Skip to main content
Top
Published in: Current Neurology and Neuroscience Reports 9/2014

01-09-2014 | Headache (RB Halker, Section Editor)

Injecting Under Pressure: The Pain of Low CSF Pressure Headache Responsive to Botulinum Toxin Injections

Authors: Paul G. Mathew, F. Michael Cutrer

Published in: Current Neurology and Neuroscience Reports | Issue 9/2014

Login to get access

Abstract

Low intracranial pressure headaches can, at times, be refractory to treatment including multiple blood patches and preventative medications. Imaging studies are often unable to demonstrate a cerebrospinal fluid leak that is causing headache and other associated symptoms. Onabotulinum toxin A (BTX) injection is a treatment that has proven efficacy for the treatment of chronic migraine and potentially other headache disorders. We report a patient with a long standing history of refractory low pressure headaches with brain imaging that demonstrated brain sag, and no CSF leak could be identified. She received no sustained benefit from numerous blood patches, and was unresponsive or intolerant to multiple preventative medications. With BTX treatment, the patient continued to have daily headaches, but her pain intensity improved from an average 7/10 to 3/10. This benefit has been sustained over 7 years. This case suggests that BTX may be an effective treatment for headaches due to low intracranial pressure. It also suggests that the beneficial effects of BTX in the treatment of headaches occur through a direct modulation of the nociceptive system rather than merely induction of pericranial muscle relaxation.
Literature
1.
go back to reference Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40:277–80.PubMedCrossRef Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40:277–80.PubMedCrossRef
2.
go back to reference Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56:1290–3.PubMedCrossRef Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56:1290–3.PubMedCrossRef
3.
go back to reference Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open label study. Otolaryngol Head Neck Surg. 2000;123(6):669–76.PubMedCrossRef Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open label study. Otolaryngol Head Neck Surg. 2000;123(6):669–76.PubMedCrossRef
4.
go back to reference Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;0:0333102410364677v1. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;0:0333102410364677v1.
5.
go back to reference Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci. 1997;152(2):132–5.PubMedCrossRef Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci. 1997;152(2):132–5.PubMedCrossRef
6.
go back to reference Antonucci F, Rossi C. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28(14):3689–96.PubMedCrossRef Antonucci F, Rossi C. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28(14):3689–96.PubMedCrossRef
7.
go back to reference Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49(10):1466–78.PubMedCrossRef Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49(10):1466–78.PubMedCrossRef
8.
go back to reference Relja M, Telarović S. Botulinum toxin in tension-type headache. J Neurol. 2004;251 Suppl 1:12–4. Relja M, Telarović S. Botulinum toxin in tension-type headache. J Neurol. 2004;251 Suppl 1:12–4.
9.
go back to reference Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007;8(4):236–41 [Epub Sep 24, 2007].PubMedCentralPubMedCrossRef Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007;8(4):236–41 [Epub Sep 24, 2007].PubMedCentralPubMedCrossRef
10.
go back to reference Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000;40(3):231–6.PubMedCrossRef Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000;40(3):231–6.PubMedCrossRef
11.
go back to reference Mokri B, Hunter SF, Atkinson JLD, Piepgras DG. Orthostatic headaches caused by CSF leak but with normal CSF pressures. Neurology. 1998;51:786–90.PubMedCrossRef Mokri B, Hunter SF, Atkinson JLD, Piepgras DG. Orthostatic headaches caused by CSF leak but with normal CSF pressures. Neurology. 1998;51:786–90.PubMedCrossRef
12.
go back to reference Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014.
Metadata
Title
Injecting Under Pressure: The Pain of Low CSF Pressure Headache Responsive to Botulinum Toxin Injections
Authors
Paul G. Mathew
F. Michael Cutrer
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 9/2014
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-014-0477-1

Other articles of this Issue 9/2014

Current Neurology and Neuroscience Reports 9/2014 Go to the issue

Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis

Behavior (H Kirshner, Section Editor)

Hashimoto’s Encephalopathy: A Brief Review

Neuro-Oncology (LE Abrey, Section Editor)

Intracranial Cystic Lesions: A Review